Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPulmonologyModa Health Cinqair (reslizumab) Prior Auth Covera…
    Ask Trek AI about this page
    CurrentModa HealthPolicy M-P0273

    Cinqair (reslizumab) (Intravenous)

    Customize your policy alerts

    Sign up for Moda Health Policy M-P0273 alerts

    Get alerted when Policy M-P0273 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy M-P0273 defines prior authorization, dosing limits, initial and renewal medical necessity criteria, contraindicated concomitant therapies, and administration dosing for Cinqair (reslizumab) for Moda Health members.

    Policy Summary
    PayerModa Health
    PolicyCinqair (reslizumab) (Intravenous)
    Policy CodePolicy M-P0273
    Change TypeNo material changes
    Effective DateMar 3, 2026
    Last ReviewMar 3, 2026
    Next Review DateMar 3, 2026
    Key ActionObtain prior authorization; approvals (initial and renewal) are valid for 12 months and renewals require documentation of clinical benefit and ongoing criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsPA length
    400Max HCPCS units/4wk
    3 mg/kg q4wDosing
    two agentsRequired prior biologics
    J2786

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    HCPCS code
    59310-0610-xxNDC

    Coverage Criteria for Cinqair (reslizumab)

    Initial Therapy (Commercial)

    Covered when ALL of the following are met for commercial members:

    Commercial initial criteria

    • Continuation eligibility: Member treated with the requested agent within the past 90 days (starting on samples is not approvable) OR prescriber states member treated within past 90 days and is at risk if therapy changed.

      Agents eligible for continuation

    • Severe eosinophilic asthma confirmation: Diagnosis confirmed by ONE of: baseline blood eosinophils >=150 cells/microliter while on high-dose inhaled corticosteroids or daily oral corticosteroids; OR FeNO >=20 ppb while on high-dose inhaled corticosteroids or daily oral corticosteroids; OR sputum eosinophils >=2% while on high-dose inhaled corticosteroids or daily oral corticosteroids; AND ONE of: history of uncontrolled asthma (>=2 systemic corticosteroid bursts in past 12 months OR hospitalization/mechanical ventilation/ER/urgent care visit in past 12 months OR controlled asthma that worsens when corticosteroids are tapered) OR baseline FEV1 <80% predicted.

      Nested diagnostic and exacerbation criteria

    • Controller therapy and adherence: If not currently on a biologic, member treated with a maximally tolerated inhaled corticosteroid for >=3 months and adherent for 90 days within the past 120 days; OR if currently treated with a biologic, member is on adequate inhaled corticosteroid therapy and adherent as specified; OR has intolerance/hypersensitivity/contraindication to inhaled corticosteroid options; AND member treated >=3 months and adherent for 90 days within past 120 days with at least one of LABA, LAMA, LTRA, or theophylline (or documented intolerance/contraindication as specified).

      Medication history and adherence requirements

    Initial Therapy (Medicaid)

    Covered when ALL of the following are met for Medicaid members:

    Medicaid initial criteria: Member has inadequate response, contraindication, or intolerance to at least a 3-month trial of TWO of: mepolizumab, dupilumab, or omalizumab; AND member meets continuation/diagnostic requirements and other criteria analogous to commercial requirements (diagnosis confirmation, controller therapy/adherence, specialist involvement, avoidance of contraindicated concomitant agents, and no FDA-labeled contraindications).

    Refer to continuation and diagnostic nodes for full requirements.

    Initial Therapy / Indication

    Covered when ALL of the following are met

    Indication and dosing: Patient has a covered diagnosis (see Covered ICD-10 Codes such as J45.50, J82.81–J82.83, J82.89) AND will receive reslizumab dosed at 3 mg/kg IV every 4 weeks.3 mg/kg every 4 weeks

    Based on policy dosing and covered diagnoses from Appendix 1

    Continuation/Renewal Therapy

    Covered upon renewal when ALL of the following are met:

    Renewal: Member was previously approved for the requested agent through the plan's prior authorization process; AND member has had clinical benefit with the requested agent; AND if severe eosinophilic asthma, member treated within the past 90 days and compliant with asthma control therapy (e.g., ICS, ICS/LABA, LTRA, LAMA, theophylline); AND prescriber is a specialist or has consulted one; AND member is not using contraindicated concomitant immunomodulators unless prescribing information does not limit combination use AND there is supporting evidence for the combination; AND member has no FDA-labeled contraindications to the agent.

    Clinical benefit documentation required

    Continuation Eligibility

    Continuation eligibility rules and compendia support:

    Continuation eligibility general: All target agents are eligible for continuation if member treated with requested agent within past 90 days (starting on samples is not approvable) OR prescriber documents treatment within past 90 days and risk if therapy changed.

    Compendia allowed: AHFS, DrugDex 1 or 2a, or NCCN 1 or 2a

    Contraindicated Concomitant Therapy

    Not covered/contraindicated when used concomitantly with any of the following therapies

    Contraindicated concomitant therapies: Concurrent use with the listed biologic or immunomodulatory agents is contraindicated (examples include: tezepelumab [Tezspire], omalizumab [Xolair], multiple IL inhibitors, TNF inhibitors, JAK inhibitors, and other agents listed in policy Appendix 'Agents NOT to be used Concomitantly').

    See full list in policy chunk 18

    The policy lists an extensive set of immunomodulatory and biologic agents that should not be used concomitantly with Cinqair (reslizumab) without justification. Providers requesting coverage must document any clinical rationale for concurrent use and demonstrate that concomitant therapy is necessary, supported by prescribing information or compendia, and does not increase undue risk. Absent a clear, documented justification showing medical necessity and safety, concurrent administration with agents on the policy's "Agents NOT to be used Concomitantly" list may lead to denial or require further review.

    Certain biologic and immunomodulatory agents are explicitly labeled in the policy as contraindicated as concomitant therapy with reslizumab; use of Cinqair together with these listed agents (for example, tezepelumab, omalizumab, mepolizumab, and multiple other IL/biologic or immunomodulatory products) is not allowed and will exclude coverage. Prescribers should verify the patient's medication list against the policy's contraindicated agents before submitting an authorization request.

    If the clinical submission does not meet the policy's required elements — for example, failure to document the requisite prior biologic trials, diagnostic confirmation of severe eosinophilic asthma, adherence to controller therapy, or specialist involvement — the request will be considered not medically necessary under the policy. Providers should include complete documentation of prior trials, baseline eosinophil or FeNO measurements, controller therapy history, and specialist consultation to avoid a determination of non‑medical necessity.

    For Medicare members, this policy does not replace or modify any applicable National Coverage Determinations (NCDs) or Local Coverage Determinations (LCDs). Providers must comply with relevant Medicare NCDs/LCDs where applicable; the policy notes that Medicare Part B covered diagnosis coding and contractor jurisdictional rules remain applicable and should be followed when submitting claims.

    Coding, Billing, and Dose Limits

    Covered HCPCS Codes (implied by dosing/unit limits)HCPCSCovered
    J1745Injection, reslizumab, 1 mg
    HCPCSHCPCSCovered
    J2786Injection, reslizumab, 1 mg; 1 billable unit = 1 mg
    NDCNDCCovered
    59310-0610-xxCinqair 100 mg/10 mL single-use vial
    Covered ICD-10 CodesICD-10Covered
    J45.50Severe persistent asthma, uncomplicated
    J82.81Chronic eosinophilic pneumonia
    J82.82Acute eosinophilic pneumonia
    J82.83Eosinophilic asthma
    J82.89Other pulmonary eosinophilia, not elsewhere classified
    HCPCS billing limit
    HCPCS billing limit400 billable units every 4 weeks
    Billing unit definitionHCPCS units are reported per 1 mg (see HCPCS J2786) — ensure total billed units do not exceed limit
    Limit intervalLimit applies to each rolling 4-week period
    Dose weight-based threshold
    Weight-based dose threshold3 mg per kg body weight every 4 weeks
    Administration routeIntravenous infusion

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required — 12‑month approvals

    Prior authorization is required for Cinqair; initial and renewal approvals are valid for 12 months (365 days). Renewals must be processed through the plan prior authorization process and will be renewed every 12 months thereafter.

    Note

    Consider PA per NQTL checklist (indication, cost, safety)

    Consider prior authorization for Cinqair based on the drug indication and cost as part of the plan's NQTL assessment; utilization management factors cited include indication, safety/efficacy, and drug cost.

    Step Therapy

    Document trials of two prior biologics (commercial)

    Definitions and Diagnostic Thresholds

    Severe eosinophilic asthma (diagnostic confirmation)
    Diagnostic confirmation — blood eosinophilsBaseline blood eosinophils ≥150 cells/µL while on high‑dose inhaled corticosteroid (ICS) or daily oral corticosteroids
    Diagnostic confirmation — FeNOFeNO ≥20 parts per billion (ppb) while on high‑dose ICS or daily oral corticosteroids
    Diagnostic confirmation — sputum eosinophilsSputum eosinophils ≥2% while on high‑dose ICS or daily oral corticosteroids
    Additional diagnostic criteriaAND evidence of uncontrolled asthma (e.g., ≥2 steroid bursts in past 12 months, asthma hospitalization/ventilation/ER visit in past 12 months, or worsening when steroids tapered) or baseline FEV1 <80% predicted
    3 mg/kg IV every 4 weeks for severe eosinophilic asthma
    Dosing regimen

    Background

    Cinqair (reslizumab) is an intravenous monoclonal antibody that targets interleukin‑5 (anti–IL‑5) and is indicated for treatment of severe eosinophilic asthma. The policy specifies weight‑based dosing of 3 mg/kg IV every 4 weeks and requires objective evidence of eosinophilic inflammation and uncontrolled disease despite appropriate controller therapy; specialist prescriber involvement and prior authorization are required per the policy.

    Revision History

    2026-03-03policy_reviewLatest

    Policy M-P0273 last reviewed; prior authorization length and renewal specified as 12 months (365 days).

    Policy Summary
    PayerModa Health
    PolicyCinqair (reslizumab) (Intravenous)
    Policy CodePolicy M-P0273
    Change TypeNo material changes
    Effective DateMar 3, 2026
    Last ReviewMar 3, 2026
    Next Review DateMar 3, 2026
    Key ActionObtain prior authorization; approvals (initial and renewal) are valid for 12 months and renewals require documentation of clinical benefit and ongoing criteria.
    SourceLink
    On This Page
    Coverage Criteria for Cinqair (reslizumab)Coding, Billing, and Dose LimitsProvider Actions, Prior Authorization, and DocumentationDefinitions and Diagnostic ThresholdsBackgroundRevision History
    Dosing intervalEvery 4 weeks (q4w)

    For commercial members, document inadequate response, contraindication, or intolerance to at least a three‑month trial of TWO of the following agents before approval will be granted: mepolizumab, dupilumab, tezepelumab, or omalizumab.

    • Trials must be at least three (3) months in duration
    • Two distinct agents from the listed group are required for commercial members
    Prior Authorization

    Include indication and supporting clinical data with PA request

    Ensure prior authorization submission includes the specific clinical indication and relevant supporting data per policy to allow review against medical necessity criteria.

    Documentation Required

    Required clinical documentation for PA and renewal

    Include documentation of prior biologic trials with evidence of inadequate response, contraindication, or intolerance; for severe eosinophilic asthma include baseline eosinophil count, FeNO or sputum eosinophils, history of exacerbations or FEV1 as specified, medication adherence, and specialist involvement.

    • Baseline blood eosinophils ≥150 cells/µL while on high‑dose ICS or oral corticosteroids, OR FeNO ≥20 ppb while on high‑dose ICS or oral corticosteroids, OR sputum eosinophils ≥2%
    • Evidence of uncontrolled asthma (e.g., ≥2 steroid bursts in past 12 months, hospitalization/ER, or worsening when steroids tapered) or baseline FEV1 <80% predicted
    • Medication history showing prior biologic use or controller therapy adherence and specialist prescriber/consultation
    Billing Rule

    Document diagnosis, dosing, and bill with J2786 + NDC

    Document the supported ICD-10 covered diagnosis (e.g., J45.50; J82.81–J82.83; J82.89) and provide dose and administration details; bill using HCPCS J2786 with the matching NDC for Cinqair (59310-0610-xx).

    • HCPCS: J2786 — Injection, reslizumab, 1 mg; 1 billable unit = 1 mg
    • NDC: Cinqair 100 mg/10 mL single‑use vial — 59310-0610-xx
    • Covered diagnoses: J45.50, J82.81, J82.82, J82.83, J82.89
    Denial Risk

    Denial risk — missing required prior biologic trials or clinical evidence

    Failure to document required trials of prior biologic agents or lack of evidence that clinical criteria are met (diagnostic confirmation, controller therapy trials, adherence, specialist involvement, or contraindication/intolerance) can trigger denial of the request.

    Denial Risk

    Denial triggers — contraindicated concomitant therapy, billing, diagnosis mismatches

    Use of contraindicated concomitant biologic or immunomodulatory therapies, mismatched billing units or NDC, or an unsupported diagnosis will trigger denial per policy.

    • Concurrent use with listed agents (e.g., tezepelumab, omalizumab, multiple other biologics in the policy) is contraindicated unless supported by prescribing information and evidence
    • Billing must use HCPCS J2786 units consistent with dosing and include the matching NDC
    • Diagnosis must map to covered ICD‑10 codes (J45.50; J82.81–J82.89)
    3 mg/kg IV every 4 weeks
    Indication tied to dosingRecommended for severe eosinophilic asthma per policy dosing/administration
    Quantity calculationDose in mg = 3 mg × patient weight (kg); convert to HCPCS units (1 mg = 1 unit) for billing